Trial Profile
Administration of Anti-CD3 (OKT3) [muromonab CD3] in Combination With Beta-D-Glucosylceramide
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Muromonab CD3 (Primary) ; Glucosylceramide
- Indications Autoimmune disorders
- Focus Adverse reactions
- 17 Apr 2008 Sucessful results have been reported in a Hadasit media release.
- 17 Apr 2008 Status change
- 05 Mar 2008 New trial record.